Click here to close now.




















Welcome!

News Feed Item

Global Antibody Drug Conjugate Market Outlook 2018

NEW YORK, March 17, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Antibody Drug Conjugate Market Outlook 2018
http://www.reportlinker.com/p02048454/Global-Antibody-Drug-Conjugate-Market-Outlook-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

The ADC technology is not new. It dates back to the 90s. However, several issues such as specificity of the payload (drug), and poor conjugation of drug and antibody proved a setback. But, the past few years have witnessed ADCs make a glorious comeback. This can be attributed to the significant advancements that have been made in the field of linker technology as well as payload efficacy and specificity. There are currently two ADC products in the market, Adcetris and Kadcyla.

According to our report, "Global Antibody Drug Conjugate Market Outlook 2018", backed by improved understanding and better technology, the ADC market is anticipated to reach US$ 3.45 Billion by 2018. Our report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved. These drugs will take some time in order to capture their entire potential market.

The report also provides an insight into the key ADCs that are currently in pipeline. At present, only one drug, Inotuzumab Ozogamicin is in late stage clinical trial. Apart from new drug candidates, previously approved drugs are also in late stage trials for other indications. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided. These activities are aimed at combining technologies and capabilities of other companies with inherent ones for the development of ADCs.

Major drivers such as advances in linker technology and patent fencing through ADC development have been discussed. In an attempt to protect their innovative blockbuster drugs, many pharma giants are moving towards ADCs. These moves are going to have a major impact in shaping the ADC market in the coming years. On the other hand, challenges such as the high cost of production of ADCs; difficult upstream and downstream processing; safety considerations etc., will have to be taken care of.

At the end, major players of the ADC market have been discussed. A brief business overview of every player has been provided along with their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has also been done. Whereas on one hand, a player is experienced owing to previously approved ADC, on the other it has licensed ADC technology from top providers. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
1. Analyst View
2. Research Methodology
3. Antibody Drug Conjugate (ADC) - An Introduction
4. ADC Market Outlook to 2018
4.1 Adcetris
4.1.1 Market Potential
4.1.2 Market Size and Forecasts to 2018
4.2 Kadcyla
4.2.1 Market Potential

4.2.2 Market Size and Forecasts to 2018
5. Current Status and Potential of Key ADC in Pipeline
5.1 Inotuzumab Ozogamicin/CMC-544 - Pfizer
5.2 Glembatumumab Vedotin/CDX-011 - Celldex Therapeutics
5.3 SAR-3419 - Sanofi
5.4 PSMA-ADC - Progenics Pharmaceuticals
5.5 RG-7596 - Roche
5.6 RG-7593 - Roche
6. Strategic Collaborations in the ADC Industry
7. Drivers and Challenges
8. Competitive Landscape
8.1 Roche
8.2 Sanofi
8.3 Progenics
8.4 Seattle Genetics
8.5 Celldex Therapeutics

List of Figures

Figure 3 1: ADC - Mechanism of Action
Figure 4 1: Global - ADC Market (Million US$), 2013 & 2018
Figure 4 2: Global - Adcetris Market (Million US$), 2011 & 2012
Figure 4 3: Global - Adcetris Market (Million US$), 2013 & 2018
Figure 4 4: Global - Kadcyla Market (Million US$), 2013 & 2018

List of Tables

Table 4 1: Potential Patients for Adcetris (2012)
Table 4 2: Ongoing Trials for Adcetris
Table 4 3: Potential Patients for Kadcyla (2012)
Table 4 4: Ongoing Trials for Kadcyla
Table 5 1: ADCs in Pipeline
Table 6 1: Strategic Collaborations in the ADC Industry
Table 8 1: Roche - ADCs in Pipeline
Table 8 2: Roche - Strengths and Weaknesses
Table 8 3: Sanofi - ADCs in Pipeline
Table 8 4: Sanofi - Strengths and Weaknesses
Table 8 5: Progenics - ADCs in Pipeline
Table 8 6: Progenics - Strengths and Weaknesses
Table 8 7: Seattle - ADCs in Pipeline
Table 8 8: Seattle Genetics - ADC Collaborator Pipeline
Table 8 9: Seattle - Strengths and Weaknesses
Table 8 10: Celldex Therapeutics - ADC Pipeline
Table 8 11: Celldex Therapeutics - Strengths and Weaknesses

To order this report: Global Antibody Drug Conjugate Market Outlook 2018
http://www.reportlinker.com/p02048454/Global-Antibody-Drug-Conjugate-Market-Outlook-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
Between the compelling mockups and specs produced by your analysts and designers, and the resulting application built by your developers, there is a gulf where projects fail, costs spiral out of control, and applications fall short of requirements. In his session at @DevOpsSummit, Charles Kendrick, CTO and Chief Architect at Isomorphic Software, presented a new approach where business and development users collaborate – each using tools appropriate to their goals and expertise – to build mocku...
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
SYS-CON Events announced today that VividCortex, the monitoring solution for the modern data system, will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. The database is the heart of most applications, but it’s also the part that’s hardest to scale, monitor, and optimize even as it’s growing 50% year over year. VividCortex is the first unified suite of database monitoring tools specifically desi...
Graylog, Inc., has added the capability to collect, centralize and analyze application container logs from within Docker. The Graylog logging driver for Docker addresses the challenges of extracting intelligence from within Docker containers, where most workloads are dynamic and log data is not persisted or stored. Using Graylog, DevOps and IT Ops teams can pinpoint the root cause of problems to deliver new applications faster and minimize downtime.
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Learn how you can use the CoSN SEND II Decision Tree for Education Technology to make sure that your K–12 technology initiatives create a more engaging learning experience that empowers students, teachers, and administrators alike.
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
As organizations shift towards IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection and E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 17th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships at Com...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...